Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Gynecologic Oncology
|
February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Lucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Gynecologic Oncology
|
March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Debra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology
|
February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
B A McGregor, G P Sonpavde, L Kwak, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Courtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Science Signaling
|
February 20, 2020
Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
Alison M Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
Cheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Gynecologic Oncology
|
February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Lucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
Gynecologic Oncology
|
March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Debra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology
|
February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
David M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma
B A McGregor, G P Sonpavde, L Kwak, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2017
Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Courtney L Andersen, Matthew J Sikora, Michelle M Boisen, et al.
Science Signaling
|
February 20, 2020
Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
Alison M Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2013
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
Cheryl Lai-Lai Chiang, Lana E Kandalaft, Janos Tanyi, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Page
of 6